GlassScriptPhysician profile
Mourad Nessim
NPI 1275582058
$5,883.56
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,018 · 2020: $555 · 2021: $155 · 2022: $1,192 · 2023: $1,098 · 2024: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.87 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $953.48 | 2019-2024 | |
| Abbvie INC. | $827.98 | 2019-2024 | |
| Lilly USA, LLC | $766.01 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $510.66 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.81 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $409.04 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $382.55 | 2019-2024 | Airsupra |
| Amgen INC. | $276.11 | 2019-2020 | |
| Abbott Laboratories | $181.39 | 2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $139.27 | 2019-2020 | |
| Astellas Pharma US INC | $136.66 | 2019-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $120.88 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $116.33 | 2023-2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $109.08 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.58 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $89.93 | 2019-2020 | |
| Mylan Specialty L.P. | $64.02 | 2019 | |
| Idorsia Pharmaceuticals US INC | $59.00 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $37.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.07 | 2019 | |
| Exact Sciences Corporation | $20.96 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $19.82 | 2023 | Gvoke Hypopen |
| Gilead Sciences, INC. | $15.05 | 2019 | |
| Kaleo, INC. | $15.05 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.77 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.68 | 2019 | |
| Allergan, INC. | $14.50 | 2020 | |
| Roche Diabetes Care, INC. | $13.54 | 2019 | |
| Sanofi Pasteur INC. | $12.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mourad Nessim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.